Samsung Electronics Shares Jump on HBM4 Mass Production Report 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CAMBRIDGE, Mass., Oct. 14, 2016 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.
“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”
The following posters have been scheduled for presentation:
| Number | Poster Title | Presenter | Time |
| #283 | Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break model | Reynald Lescarbeau, Ph.D. Computational Scientist, Bioinformatics | October 19, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #280 | Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components | David Morrissey, Ph.D. Chief Technology Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #320 | DNA repair events after cleavage by CRISPR/Cas9 are not random | Walter Strapps, Ph.D. Senior Director, Biology | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #310 | Translating CRISPR/Cas9 genome editing into therapeutics | Tom Barnes, Ph.D. Chief Scientific Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 [email protected] Investor Contacts: John Graziano Trout Group +1 646-378-2942 [email protected] Chad Rubin Trout Group +1 646-378-2947 [email protected]
